NPXe Announces the Appointment of Jim McAuliffe as Chief Financial Officer

20 August 2018

 

ABINGDON, UNITED KINGDOM AND BUFFALO, USA – NPXe Limited (“NeuroproteXeon” or “NPXe”), today announces the appointment of Jim McAuliffe as Chief Financial Officer with effect from 7 August 2018.   

Jim is a financial leader with a wide range of experience in both the public and private sectors for the past 25 years. Prior to joining NeuroproteXeon, Jim worked at Gibraltar Industries, Uni-Select USA, Rigidized Metals Corp. and Koike Aronson/Ransome. His professional career began at PriceWaterhouse. Jim played an integral role in many complex financial transactions including registered public debt offerings, acquisition and divestiture reporting. Jim earned a BS and MBA from the University at Buffalo and a CPA from the state of New York.

Bill Burns, Chief Executive Officer at NeuroproteXeon said: Jim is joining NeuroproteXeon at an extremely important time in the Company’s development and the wealth of experience he brings with him will be invaluable to us as we plan for future growth.  I am very pleased to welcome a professional of Jim’s calibre to the leadership team and look forward to working with him.”

Commenting on his appointment Jim McAuliffe, said: I am delighted to be joining NeuroproteXeon and am excited by the potential of its XENEX™ product to improve the survival and functional capabilities of resuscitated cardiac arrest patients.  I look forward to working with Bill and the rest of the management team and Board in contributing to the Company’s future success.”

 

About NPXe Limited

NPXe Limited is developing XENEX™ (xenon gas for inhalation) for the treatment of Post-Cardiac Arrest Syndrome. The Company has a Special Protocol Agreement with the United States Food & Drug Administration (FDA) and A Scientific Working Party Agreement with the European Medicines Agency (EMA).  Both the FDA and EMA have provided the indication with Orphan Drug status.  Orphan status prolongs the period of market exclusivity post approval. Mallinckrodt has licensed the rights to market XENEX™ in North America, Australia and Japan.  Linde Group has licensed the rights to market XENEX™ in the EU, United Kingdom, Norway, Switzerland and Iceland.

 

Contacts:

NeuroproteXeon                                           Consilium (PR adviser)

Carol Burns                                                          Chris Gardner, Matthew Neal, Lindsey Neville

Communications Director                                neuroprotexeon@consilium-comms.com

Carol.burns.op@neuroprotexeon.com           Phone: +44 (0)20 3709 5700

Phone: +1-716-332-7200 Ext 155                  

 

2888560 v1

DISCLAIMER – IMPORTANT

ELECTRONIC VERSIONS OF THE MATERIALS YOU ARE SEEKING TO WHICH THIS GATEPOST GIVES ACCESS ARE BEING MADE AVAILABLE ON THIS WEBSITE BY NEUROPROTEXEON LIMITED (“NPXe”) IN GOOD FAITH AND ARE FOR INFORMATION PURPOSES ONLY.
THE MATERIALS TO WHICH THIS GATEPOST GIVE ACCESS ARE NOT DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN OR RESIDENT IN (OR ORGANISED OR INCORPORATED UNDER THE LAWS OF) THE UNITED STATES OR U.S. PERSONS (AS SUCH TERM IS DEFINED IN REGULATION S (“REGULATION S”) UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)), WHEREVER LOCATED, OR PERSONS RESIDENT OR LOCATED IN AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE THE EXTENSION OF AVAILABILITY OF THE MATERIALS TO WHICH YOU ARE SEEKING ACCESS WOULD BREACH ANY APPLICABLE LAW OR REGULATION.
The materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States, Australia, Canada, Japan, or in any jurisdiction in which such offers or sales are unlawful (the “Excluded Territories”) or to U.S. Persons (as such term is defined in Regulation S), wherever located. Any securities issued in connection with an offering have not been and will not be registered under the Securities Act or under any applicable securities laws of any state, province, territory, county or jurisdiction of the United States, Australia, Canada or Japan. Accordingly, unless an exemption under relevant securities laws is applicable, any such securities may not be offered, sold, resold, taken up, exercised, renounced, transferred, delivered or distributed, directly or indirectly, in or into the United States, Australia, Canada, Japan, or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration of such securities in, the relevant jurisdiction. There will be no public offer of securities in the United States.
The materials are only addressed to and directed at persons in member states of the European Economic Area (“EEA”) who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC and any amendments thereto including Directive 2010/73/EU to the extent implemented in the relevant EEA member state) and any relevant implementing measure in the relevant member state of the EEA (“Qualified Investors”). In addition, in the United Kingdom, the materials are being distributed only to, and are directed at Qualified Investors (as defined above) who are (a) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (b) high net worth entities, and other persons falling within Article 49(2)(a) to (d) of the Order to whom they may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). Any investment or investment activity to which these materials relates are available only to Relevant Persons in the United Kingdom and Qualified Investors in any member state of the EEA other than the United Kingdom, and will only be engaged with such persons.
If you are not permitted to view materials on this website or are in any doubt as to whether you are permitted to view these materials, please exit this webpage. These materials must not be released or otherwise forwarded, distributed or sent to U.S. Persons or otherwise in or into the United States, Australia, Canada, Japan, or any jurisdiction in which such offers or sales are unlawful. Persons receiving such documents (including custodians, nominees and trustees) must not distribute or send them to U.S Persons or otherwise in, into or from the United States, Australia, Canada or Japan.
Confirmation of understanding and acceptance of disclaimer
I warrant that I am not a resident of, or located in, the United States, Australia, Canada or Japan or any other jurisdiction where accessing these materials is unlawful, nor a U.S. Person, and I agree that I will not transmit or otherwise send any materials contained in this website to any U.S Person or any other person in the United States, Australia, Canada, Japan or any other jurisdiction where to do so would breach applicable local law or regulation.
I have read and understood the disclaimer set out above. I understand that it may affect my rights and I agree to be bound by its terms. I confirm that I am permitted to proceed to electronic versions of the materials.
NeuroproteXeon does not accept any responsibility for any contravention of applicable securities laws and regulations by individuals as a result of false information provided by such individuals.
[I ACCEPT] [DON’T ACCEPT]